Brain Tumor Pathology

, Volume 32, Issue 3, pp 169–175 | Cite as

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas

  • Shingo Takano
  • Yukinari Kato
  • Tetsuya Yamamoto
  • Xing Liu
  • Eiichi Ishikawa
  • Mika K. Kaneko
  • Satoshi Ogasawara
  • Masahide Matsuda
  • Masayuki Noguchi
  • Akira Matsumura
Original Article


Isocitrate dehydrogenase (IDH) mutation is a valuable prognostic marker and a tool for decision-making for glioma treatment. An algorithm for IDH mutation screening was recently proposed—it consists of a two-step process of an initial search for the most common IDH1-R132H mutation using immunohistochemistry (IHC)-based assay, followed by DNA-based analysis of IHC-negative or -equivocal cases. Here, we report that immunohistochemistry using two mutation-specific anti-IDH monoclonal antibodies (mAbs)—an IDH1-R132H-specific mAb (clone HMab-1) and a multi-specific mAb (clone MsMab-1)—is easy and reliable for IDH mutation screening. We investigated the IDH status of 54 grade III gliomas. For the first screening, we used HMab-1 IHC and for the second, (of HMab-1-negative cases) we used MsMab-1 IHC. The double IHC screening results were confirmed using sequence analysis (100 % specificity and 100 % sensitivity). Thirty of 54 cases (55.6 %) had IDH mutations and the remaining 24 were of the IDH wild type; moreover, the screening results predicted grade III glioma prognosis. IDH sequencing procedures are popular but inconsistent across laboratories. By contrast, double IHC screening using HMab-1 and MsMab-1 is very reliable for detecting IDH1/2 mutations and can predict survival in grade III glioma patients.


Glioma IDH Immunohistochemistry Monoclonal antibody Mutation 



We thank Yoshiko Tsukada, Makiko Miyakawa, Takuro Nakamura, Noriko Saidoh, and Kanae Yoshida for their excellent technical assistance. This work was supported in part by Grants-in-Aid for Scientific Research (to S.T., No. 24390339; to Y.K., No. 25462242) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan; by the Platform for Drug Discovery, Informatics, and Structural Life Science from MEXT, Japan (to Y.K.); by the Basic Science and Platform Technology Program for Innovative Biological Medicine from MEXT, Japan (to Y.K.); by the Regional Innovation Strategy Support Program from MEXT, Japan (to Y.K.); by a Health Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan (to Y.K.); and by the Japan Brain Foundation (to S.T.) and the Japanese Foundation for Multidisciplinary Treatment of Cancer (to S.T.).

Conflict of interest

The authors declare no conflicts of interest.

Supplementary material

10014_2015_214_MOESM1_ESM.pptx (393 kb)
Supplementary Figure 1. Background staining with MsMab-1. IDH1-R132H case (A, B), IDH wild-type case (C, D). HMab-1 stained nicely IDH1-R132H (A) and revealed no stain against IDH wild type (C) using LSAB2 kit. By contrast, MsMab-1 revealed background staining both against IDH1-R132H (B) and IDH wild type (D) using LSAB2 kit. However, MsMab-1 revealed no background staining against the same case using Envision + kit (see Supplementary Fig. 2F) (PPTX 393 kb)
10014_2015_214_MOESM2_ESM.pptx (690 kb)
Supplementary Figure 2. Comparison between HMab-1 and MsMab-1 against IDH1-R132H. HMab-1 (A, C, E) detected IDH1-R132H more strongly and frequently than MsMab-1 (B, D, F) (PPTX 689 kb)


  1. 1.
    Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154PubMedCrossRefGoogle Scholar
  3. 3.
    Cairncross JG, Wang M, Jenkins RB et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–790PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Preusser M, Capper D, Hartmann C (2011) IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 30:217–230PubMedCrossRefGoogle Scholar
  5. 5.
    Arita H, Narita Y, Matsushita Y et al (2014) Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol Apr 19. [Epub ahead of print] (PMID:24748374)Google Scholar
  6. 6.
    von Deimling A, Korshunov A, Hartmann C (2011) The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74–87CrossRefGoogle Scholar
  7. 7.
    Capper D, Weissert S, Balss J et al (2009) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254PubMedCrossRefGoogle Scholar
  8. 8.
    Takano S, Tian W, Matsuda M et al (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123PubMedCrossRefGoogle Scholar
  9. 9.
    Kato Y (2014) Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol in press 2014 Oct 17. [Epub ahead of print]Google Scholar
  10. 10.
    Kaneko MK, Ogasawara S, Kato Y (2013) Establishment of a multi-specific monoclonal antibody MsMab-1 recognized both IDH1 and IDH2 mutations. Tohoku J Exp Med 230:103–109CrossRefGoogle Scholar
  11. 11.
    Liu X, Kato Y, Kaneko MK et al (2013) Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med 2:803–814PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Takano S, Kato Y, Yamamoto T et al (2012) Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108:361–373PubMedCrossRefGoogle Scholar
  13. 13.
    Kaneko MK, Morita S, Tsujimoto Y et al (2013) Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biol Biophys Res Commun 432:40–45CrossRefGoogle Scholar
  14. 14.
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2014) Central nervous system cancers, vol 1. Available via Accessed 14 Mar 2014
  15. 15.
    Preusser M, Mv Bent (2013) Clinical neuropathology practice news 2-2013: immunohistochemistry pins IDH in glioma—molecular testing procedures under scrutiny. Clin Neuropathol 32(2):82–83PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Catteau A, Girardi H, Monville F et al (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58. doi: 10.1186/2051-5960-2-58 PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Loussouarn D, Le Loupp AG, Frenel JS et al (2012) Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 40:2058–2062PubMedGoogle Scholar
  18. 18.
    Preusser M, Wohrer A, Stary S et al (2011) Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70:715–723PubMedCrossRefGoogle Scholar
  19. 19.
    van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597–1604PubMedCrossRefGoogle Scholar
  20. 20.
    Agarwal S, Sharma MC, Jha P et al (2013) Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 15:718–726PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    van den Bent MJ, Hartmann C, Preusser M et al (2013) Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173–178PubMedCrossRefGoogle Scholar
  22. 22.
    Kaneko MK, Tian W, Takano S et al (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation. Biochem Biophys Res Commun 406:608–613PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2015

Authors and Affiliations

  • Shingo Takano
    • 1
  • Yukinari Kato
    • 2
  • Tetsuya Yamamoto
    • 1
  • Xing Liu
    • 2
  • Eiichi Ishikawa
    • 1
  • Mika K. Kaneko
    • 2
  • Satoshi Ogasawara
    • 2
  • Masahide Matsuda
    • 1
  • Masayuki Noguchi
    • 3
  • Akira Matsumura
    • 1
  1. 1.Department of Neurosurgery, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  2. 2.Department of Regional InnovationTohoku University Graduate School of MedicineSendaiJapan
  3. 3.Department of Pathology, Faculty of MedicineUniversity of TsukubaTsukubaJapan

Personalised recommendations